43 results
Page 2 of 3
6-K
EX-99.2
iqwszn4pat4q5cufu63q
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
7quwomfwzbqx4
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
4ibj30 lm7hhsi
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
394w 5fli1
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
EX-99.2
4ujsintibo2xz1
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
oeyhzwt4jw11
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
5jzqdi3zbmwvd4xwj xi
31 Aug 21
Galapagos announces planned retirement of CEO
3:46pm
6-K
EX-99.1
fv2 65hd6
23 Jun 21
Galapagos announces departure of CSO Piet Wigerinck later this year
6:00am
6-K
EX-99.1
1wu8q
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
6-K
EX-99.1
swcans ebrodqh
24 Jan 20
Galapagos appoints Michele Manto as Chief Commercial Officer
8:52am
6-K
EX-99.7
w4ozds1bn669p
20 Sep 19
Current report (foreign)
4:07pm
6-K
EX-99.1
lctzm q51haj4b87
13 Sep 18
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
12:00am
6-K
EX-99.1
2wzq hecxf5lk2i5dgor
19 Jul 18
Current report (foreign)
6:05am
6-K
EX-99.1
lkbjue p9
2 May 18
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
6:00am